Showing 2081-2090 of 2314 results for "".
- Coopervision Global Charity Releases its Annual Impact Report Highlighting Achievementshttps://modernod.com/news/coopervision-global-charity-releases-its-annual-impact-report-highlighting-achievements/2479515/As pediatric myopia increases globally in prevalence and severity, CooperVision remains committed to supporting programs such as “Our Children’s Vision” implemented by the Brien Holden Foundation that prioritize children’s eye health. Over the last 3 years, CooperVision has donated a
- Asymptomatic Spread of Coronavirus is ‘Very Rare,’ WHO Sayshttps://modernod.com/news/asymptomatic-spread-of-coronavirus-is-very-rare-who-says/2477878/Coronavirus patients without symptoms aren’t driving the spread of the virus, World Health Organization officials said Monday, casting doubt on concerns by some researchers that the disease could be difficult to contain due to asymptomatic infections, CNBC
- Nurses Developed Eye Cysts While Treating COVID-19 Patientshttps://modernod.com/news/nurses-developed-eye-cysts-while-treating-covid-19-patients/2477879/Nurses in Paris developed eye problems while using eye protection to care for critically ill patients in COVID-19 intensive-care wards, Reuters reported, citing a new report by French doctors. The nurses were prescribed an eye ointm
- Implandata Launches Eyemate IOP-Tracking Service for Remote Monitoring and Improved Glaucoma Carehttps://modernod.com/news/implandata-launches-eyemate-iop-tracking-service-for-remote-monitoring-and-improved-glaucoma-care/2477870/Implandata Ophthalmic Products announced the launch of its web-based Eyemate IOP-Tracking Service for remote monitoring and management of glaucoma. The Eyemate provides eye doctors with IOP measurements collected anytime under patients’ normal life conditions. “Remote IOP monitoring provid
- AbbVie Enters Deal to Develop Antibody Therapeutic for COVID-19https://modernod.com/news/abbvie-enters-deal-to-develop-antibody-therapeutic-for-covid-19/2477869/AbbVie entered into a collaboration with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop an antibody therapeutic to prevent and treat COVID-19, the parties announced Friday. The fully human, neutralising antibody 47D11, which targets the conserved domain of the spike pro
- BVI Launches CryoTreq for Treatment of Retinal Tears and Detachmentshttps://modernod.com/news/bvi-launches-cryotreq-for-treatment-of-retinal-tears-and-detachments/2477863/BVI announced the European launch of CryoTreq—a single-use, handheld cryosurgery device for ophthalmology. The device functions without external connections to equipment, gas tanks, or power and does not require any service or maintenance. CryoTreq enables a minimally invasive ab externo a
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib
- Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-first-phase-3-trial-of-ncx-470-in-glaucoma/2477855/Nicox announced the initiation of the first phase 3 clinical trial, Mont Blanc, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, by enrolling the first 12 patients. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating
- Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidatehttps://modernod.com/news/adverum-biotechnologies-announces-new-infinity-phase-2-trial-for-dme-drug-candidate/2477842/Adverum Biotechnologies announced the initiation of INFINITY, a phase 2, multicenter, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME). The company also reported financial resul